Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Retatrutide vs Semaglutide

Q: What is the difference between Retatrutide and Semaglutide?

Retatrutide is a GLP-1 compound (Subcutaneous route) - Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. Semaglutide is a GLP-1 compound (Subcutaneous route) - Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects.

Q: Which has a longer half-life, Retatrutide or Semaglutide?

Semaglutide has the longest published plasma half-life (~6.9 days (165 h)), compared with Retatrutide (~6.0 days (144 h)).

Q: How often is each compound dosed in the research literature?

Retatrutide: once weekly at a published dose range of 2–12 mg; Semaglutide: once weekly at a published dose range of 0.25–2.4 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Retatrutide and Semaglutide for research use?

Yes - Retatrutide, Semaglutide are available from New-U Research Compounds as lab-verified (>99% HPLC) compounds.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

GLP1-RC-RT

Retatrutide

Triple receptor agonist

GLP-1R · GIPR · GCGR

GLP1-RC-SM

Semaglutide

GLP-1R agonist

GLP-1R

Key research differences

Retatrutide Semaglutide Receptor profile GLP-1R · GIPR · GCGR GLP-1R Development status Investigational Approved therapeutic molecule Published half-life ~6.0 days (144 h) ~6.9 days (165 h) Research distinction Adds glucagon receptor agonism Selective GLP-1R agonism

Published research parameters

Retatrutide LY3437943 View Retatrutide → Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Receptor profile GLP-1R · GIPR · GCGR GLP-1R Class Triple receptor agonist GLP-1R agonist Plasma half-life ~6.0 days (144 h) ~6.9 days (165 h) Time to Cmax 36 h 24 h Development status Investigational Approved therapeutic molecule Study context Peer-reviewed human PK Regulatory label PK Primary publications Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023) FDA Wegovy USPI — half-life ~1 week (165 h) (2024) Summary Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects.

View published study parameters

Retatrutide LY3437943 View Retatrutide → Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Route in published studies Subcutaneous Subcutaneous Published study interval Once weekly Once weekly Published dose range 2–12 mg 0.25–2.4 mg Published study regimen 2 → 4 → 6 → 8 → 12 mg 0.25 → 0.5 → 1 → 1.7 → 2.4 mg

Source references

Jastreboff AM et al.

New England Journal of Medicine · 2023

Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)

Rosenstock J et al.

The Lancet · 2023

Rosenstock J et al., Lancet 402:529 (titration arms) (2023)

FDA Wegovy USPI — half-life ~1 week (165 h)

FDA prescribing information · 2024

FDA Wegovy USPI — half-life ~1 week (165 h) (2024)

STEP 1 trial — NEJM 384:989 (titration schedule)

New England Journal of Medicine · 2021

STEP 1 trial — NEJM 384:989 (titration schedule) (2021)

Hall S et al.

Clinical Pharmacokinetics · 2018

Hall S et al., Clin Pharmacokinet 57:1571 (Cmax ~24 h SC) (2018)

Frequently asked questions

What is the difference between Retatrutide and Semaglutide?

Which has a longer half-life, Retatrutide or Semaglutide?

How often is each compound dosed in the research literature?

Can you buy Retatrutide and Semaglutide for research use?

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research